MedPath

成都欣捷高新技术开发股份有限公司

Ownership
-
Established
2000-09-18
Employees
-
Market Cap
-
Website
http://www.giantech.net.cn

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

26

NMPA:26

Drug Approvals

Diprophylline Injection

Product Name
二羟丙茶碱注射液
Approval Number
国药准字H20254515
Approval Date
Jun 10, 2025
NMPA

Composite Potassium Hydrogen Phosphate Injection

Product Name
复合磷酸氢钾注射液
Approval Number
国药准字H20254092
Approval Date
May 13, 2025
NMPA

Famotidine Injection

Product Name
法莫替丁注射液
Approval Number
国药准字H20253828
Approval Date
Apr 8, 2025
NMPA

Epinephrine Hydrochloride Injection

Product Name
盐酸肾上腺素注射液
Approval Number
国药准字H20253602
Approval Date
Mar 11, 2025
NMPA

Potassium Chloride Injection

Product Name
氯化钾注射液
Approval Number
国药准字H20249480
Approval Date
Dec 1, 2024
NMPA

Pamidronate Disodium Injection

Product Name
帕米膦酸二钠注射液
Approval Number
国药准字H20244922
Approval Date
Sep 19, 2024
NMPA

Bromhexine Hydrochloride Tablets

Product Name
盐酸溴己新片
Approval Number
国药准字H20244820
Approval Date
Sep 3, 2024
NMPA

Bumetanide Injection

Product Name
布美他尼注射液
Approval Number
国药准字H20244549
Approval Date
Jul 30, 2024
NMPA

Isoprenaline Hydrochloride Injection

Product Name
盐酸异丙肾上腺素注射液
Approval Number
国药准字H20244012
Approval Date
Jun 11, 2024
NMPA

Isoprenaline Hydrochloride Injection

Product Name
盐酸异丙肾上腺素注射液
Approval Number
国药准字H20244011
Approval Date
Jun 11, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.